MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis PatientsJohn Mascarenhas, Srđan Verstovšek, Suresh Bobba et al.|Blood|2020Cited by 21
MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST TrialOksana Zavidij, Patrick Trojer, Patricia J. Keller et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 4
The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem CellsJennifer A. Mertz, Mohamed E. Salama, Patricia J. Keller et al.|Blood|2020Cited by 3
Poster: MPN-343: The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST TrialOksana Zavidij, Patrick Trojer, Patricia J. Keller et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 1